Can we modulate the clinical course of inflammatory bowel diseases by our current treatment strategies?

Digestive Diseases

Volumn 27, Issue 4, 2009, Pages 516-521

  Cosnes, Jacques ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Anti TNF; Inflammatory bowel disease, clinical course; Inflammatory bowel disease, natural history; Thiopurines, efficacy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

COLON RESECTION; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FOLLOW UP; HUMAN; ILEUM RESECTION; MAINTENANCE THERAPY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; REVIEW; ULCERATIVE COLITIS;

HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME;

EID: 70449493503     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000233291     Document Type: Review

References (39)

1. Rutgeerts P, Vermeire S, Van Assche G: Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182-1197.
2. Cosnes J, Cattan S, Blain A, et al: Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250.
3. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J: Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-782.
4. Vermeire S, Van Assche G, Rutgeerts P: Perianal Crohn's disease: classification and clinical evaluation. Dig Liver Dis 2007; 39: 959-962.
5. Schwartz DA, Loftus EV Jr, Tremaine WJ, et al: The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122: 875-880.
6. Cosnes J: Crohn's disease phenotype, prognosis, and long-term complications: what to expect? Acta Gastroenterol Belg 2008; 71: 303-307.
7. Sachar DB, Bodian CA, Goldstein ES, et al: Is perianal Crohn's disease associated with intestinal fistulization? Am J Gastroenterol 2005; 100: 1547-1549.
8. Oberhuber G, Stangl PC, Vogelsang H, Schober E, Herbst F, Gasche C: Significant association of strictures and internal fistula formation in Crohn's disease. Virchows Arch 2000; 437: 293-297.
9. Munkholm P, Langholz E, Davidsen M, Binder V: Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706.
10. Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK: Clinical features and natural history of Crohn's disease. Gastroenterology 1979; 77: 898-906.
11. Sands BE, Arsenault JE, Rosen MJ, et al: Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol 2003; 98: 2712-2718.
12. Andersson P, Olaison G, Bodemar G, Nystrom PO, Sjodahl R: Surgery for Crohn colitis over a 28-year period: fewer stomas and the replacement of total colectomy by segmental resection. Scand J Gastroenterol 2002; 37: 68-73.
13. Galandiuk S, Kimberling J, Al-Mishlab TG, Stromberg AJ: Perianal Crohn disease: predictors of need for permanent diversion. Ann Surg 2005; 241: 796-802.
14. Canavan C, Abrams KR, Mayberry JF: Metaanalysis: mortality in Crohn's disease. Aliment Pharmacol Ther 2007; 25: 861-870.
15. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V: Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol 1996; 31: 260-266.
16. Langholz E, Munkholm P, Davidsen M, Binder V: Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
17. Hoie O, Wolters FL, Riis L, et al: Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007; 132: 507-515.
18. Palli D, Trallori G, Saieva C, et al: General and cancer-specific mortality of a population- based cohort of patients with inflammatory bowel disease: the Florence Study. Gut 1998; 42: 175-179.
19. Dunckley P, Jewell D: Management of acute severe colitis. Best Pract Res Clin Gastroenterol 2003; 17: 89-103.
20. Wolters FL, Russel MG, Stockbrugger RW: Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004; 20: 483-496.
21. Jess T, Riis L, Vind I, et al: Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last five decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007; 13: 481-489.
22. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241.
23. Travis SP, Farrant JM, Ricketts C, et al: Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-910.
24. Truelove SC, Willoughby CP, Lee EG, Kettlewell MG: Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2: 1086-1088.
25. Lichtiger S, Present DH, Kornbluth A, et al: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845.
26. D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P: Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112: 1475-1481.
27. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
28. Vernier-Massouille G, Balde M, Salleron J, et al: Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135: 1106-1113.
29. Hanauer SB, Feagan BG, Lichtenstein GR, et al: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
30. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE: Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-869.
31. Feagan BG, Panaccione R, Sandborn WJ, et al: Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135: 1493-1499.
32. D'Haens G, Baert F, van Assche G, et al: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667.
33. Lemann M, Mary JY, Colombel JF, et al: A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-1818.
34. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J: Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-656.
35. Colombel JF, Rutgeerts P, Reinisch W, et al: SONIC: a randomized double-blind controlled trial comparing Infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gut 2008; 57:A1.
36. Olaison G, Smedh K, Sjodahl R: Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33: 331-335.
37. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M: Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-963.
38. Regueiro M, Schraut W, Baidoo L, et al: Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136: 441-450.
39. Sampietro GM, Corsi F, Maconi G, et al: Prospective study of long-term results and prognostic factors after conservative surgery for small bowel Crohn's disease. Clin Gastroenterol Hepatol 2009; 7: 183-191